A retrospective study of efficacy of pembrolizumab in advanced urogenital cancer patients
Latest Information Update: 04 Mar 2022
Price :
$35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 04 Mar 2022 New trial record
- 01 Mar 2022 Results published in the Anticancer Research